FDA approves first CAR-T therapy for multiple myeloma

29 March 2021
multiple-myeloma-bone-marrow-big

The US Food and Drug Administration on Friday approved Abecma (idecabtagene vicleucel; ide-cel), a first-in-class B-cell maturation antigen (BCMA)-directed genetically-modified autologous T-cell immunotherapy indicated for the treatment of adult patients with relapsed or refractory multiple myeloma.

Abecma is the first cell-based gene therapy approved by the FDA for the treatment of multiple myeloma, the agency pointed out.

News of the approval saw shares of the product’s developers - US pharma major Bristol Myers Squibb (NYSE: BMY) and biotech firm bluebird bio (Nasdaq: BLUE) - edge up 1.8% and 1.2%, respectively, and also marks a significant milestone for BMS, making the latter the only company with two approved CAR-T cell therapies with two distinct targets; last month  Breyanzi (lisocabtagene maraleucel; liso-cell) was approved by the FDA.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology